Search research articles
Contact Us
Filters
Showing results (111-120 of 119) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 119 results.
The Lancet. Oncology
|
November 27, 2025
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
Shukui Qin, Shanzhi Gu, Stephen L Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial
Tanios S Bekaii-Saab, Davide Melisi, Hanneke Wilmink, et al.
Therapeutic Advances in Medical Oncology
|
January 6, 2021
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
Francesca Simionato, Camilla Zecchetto, Valeria Merz, et al.
The Oncologist
|
March 19, 2026
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection
Letizia Procaccio, Guido Giordano, Federico Nichetti, et al.
Lancet (London, England)
|
July 27, 2023
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Shukui Qin, Stephen L Chan, Shanzhi Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2016
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
Matthew P Humphries, Sreekumar Sundara Rajan, Alastair Droop, et al.
BMC Cancer
|
April 8, 2024
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
Monica Niger, Federico Nichetti, Lorenzo Fornaro, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
April 18, 2024
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022
Paolo Morgagni, Maria Bencivenga, Fatima Carneiro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 25, 2020
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic
Serena Zuliani, Ilaria Zampiva, Daniela Tregnago, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 119) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 119 results.
The Lancet. Oncology
|
November 27, 2025
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
Shukui Qin, Shanzhi Gu, Stephen L Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial
Tanios S Bekaii-Saab, Davide Melisi, Hanneke Wilmink, et al.
Therapeutic Advances in Medical Oncology
|
January 6, 2021
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
Francesca Simionato, Camilla Zecchetto, Valeria Merz, et al.
The Oncologist
|
March 19, 2026
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection
Letizia Procaccio, Guido Giordano, Federico Nichetti, et al.
Lancet (London, England)
|
July 27, 2023
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Shukui Qin, Stephen L Chan, Shanzhi Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2016
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
Matthew P Humphries, Sreekumar Sundara Rajan, Alastair Droop, et al.
BMC Cancer
|
April 8, 2024
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
Monica Niger, Federico Nichetti, Lorenzo Fornaro, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
April 18, 2024
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022
Paolo Morgagni, Maria Bencivenga, Fatima Carneiro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 25, 2020
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic
Serena Zuliani, Ilaria Zampiva, Daniela Tregnago, et al.
Page
of 12